Disordered Proteostasis as a Driver of Disease in the Aging Lung

蛋白质稳态紊乱是衰老肺疾病的驱动因素

基本信息

  • 批准号:
    10620758
  • 负责人:
  • 金额:
    $ 192.72万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-07-01 至 2025-03-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY_OVERALL The Geroscience hypothesis is based on the observation that healthspan decline toward the end of life often presents with a single age-related illness that is followed by rapid accumulation of age-related complications over a relatively short period. According to this hypothesis, treating any one of these conditions without treating the fundamental biology of aging will only result in its substitution by another. The discovery of therapies that target aging biology to improve resilience and reduce frailty address the geroscience hypothesis, but administering these therapies based exclusively on chronological age will inevitably result in overtreatment. While pneumonia is more common and more severe in the elderly, most older patients with access to modern health care survive their illness. However, in the year after hospital discharge these older pneumonia survivors have an increased risk of developing age-related disorders including persistent lung injury, skeletal muscle dysfunction leading to immobility, dementia, and cognitive impairment. As such, pneumonia is a gateway for the compounding morbidity that limits healthspan at the end of life. We therefore reason that interventions that target aging biology to improve repair and promote resilience administered during recovery from pneumonia or other environmental stressors in the elderly will have broad impact. Proteostasis refers to the dynamic process by which cells control the concentration, conformation, binding interactions, and stability of individual proteins making up the proteome. In the first cycle of this award, the PPG investigators have generated substantial published and preliminary data supporting the central hypothesis of this PPG that advanced age is associated with impaired recovery from pneumonia, and metabolic interventions targeting complex I of the mitochondrial electron transport chain can reverse these changes by restoring proteostasis through the integrated stress response and ATF4. To address this fundamental question in aging, the project investigators will focus on tissue recovery after infection with the influenza A virus in mice, a clinically relevant model that can be rigorously applied across the entire lifespan and which recapitulates human biology on a time frame that can be studied in the laboratory. We will test this hypothesis in three interrelated projects/aims: Aim 1. To determine whether age-related impairments in the reparative function of alveolar macrophages can be reversed by transient low level inhibition of electron transport with complex I inhibitors via the ISR and ATF4. Aim 2. To determine whether inhibition of mitochondrial electron transport at complex I over the lifespan drives the age related impairment in recovery after influenza A pneumonia. Aim 3. To determine whether the impaired scavenger receptor function of aged resident skeletal muscle macrophages and microglia can be reversed by inhibitors of complex I via the ISR and ATF4 to improve motor and cognitive function after pneumonia.
项目概要_总体 老年科学假说是基于这样一种观察,即健康寿命在生命结束时会下降 通常表现为单一的与年龄有关的疾病,随后是与年龄有关的疾病的快速积累。 在相对较短的时间内出现并发症。根据这一假设,治疗这些疾病中的任何一种 如果不治疗衰老的基本生物学,只会导致它被另一个取代。发现 针对衰老生物学的治疗方法,以提高弹性和减少脆弱性, 假设,但管理这些治疗完全基于实际年龄将不可避免地导致 过度治疗虽然肺炎在老年人中更常见,也更严重,但大多数老年患者 获得现代医疗保健的机会,使他们在疾病中幸存下来。然而,在这些老年人出院后的一年里, 肺炎幸存者患上与年龄有关的疾病的风险增加, 损伤、导致不动的骨骼肌功能障碍、痴呆和认知障碍。因此,在本发明中, 肺炎是一个网关的复合发病率,限制健康寿命在生命的尽头。因此我们 针对衰老生物学的干预措施,以改善修复和促进恢复能力, 在从肺炎或其他环境压力中恢复的老年人将产生广泛的影响。 蛋白质稳态是指细胞控制蛋白质的浓度、构象、结合 相互作用和组成蛋白质组的单个蛋白质的稳定性。在这个奖项的第一个周期, PPG研究人员已经产生了大量的已发表的和初步的数据, 该PPG假设高龄与肺炎恢复受损相关,以及 针对线粒体电子传递链复合物I的代谢干预可以逆转这些 通过整合应激反应和ATF 4恢复蛋白质稳态来改变。为了解决这个 衰老的基本问题,该项目的研究人员将重点关注感染后的组织恢复。 小鼠中的甲型流感病毒,这是一种临床相关模型,可在整个生命周期中严格应用, 它在一个可以在实验室中研究的时间框架上概括了人类生物学。我们将测试这个 三个相互关联的项目/目标的假设: 目标1.为了确定肺泡巨噬细胞修复功能中与年龄相关的损伤是否可以 通过ISR和ATF 4用复合物I抑制剂对电子传递的短暂低水平抑制而逆转。 目标2.为了确定在整个生命周期内复合物I处的线粒体电子传递抑制是否 导致甲型流感肺炎后与年龄相关的恢复障碍。 目标3.目的:探讨老年人骨骼肌清道夫受体功能受损是否与骨骼肌的功能有关。 肌肉巨噬细胞和小胶质细胞可以通过ISR和ATF 4被复合物I的抑制剂逆转, 改善肺炎后运动和认知功能。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GR Scott Budinger其他文献

GR Scott Budinger的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GR Scott Budinger', 18)}}的其他基金

Targeting abnormal alveolar immune activation and failed epithelial repair in COVID-19
针对 COVID-19 中异常的肺泡免疫激活和失败的上皮修复
  • 批准号:
    10596990
  • 财政年份:
    2022
  • 资助金额:
    $ 192.72万
  • 项目类别:
Microglia mediate cognitive dysfunction in elderly survivors of pneumonia
小胶质细胞介导老年肺炎幸存者的认知功能障碍
  • 批准号:
    10354214
  • 财政年份:
    2022
  • 资助金额:
    $ 192.72万
  • 项目类别:
Targeting abnormal alveolar immune activation and failed epithelial repair in COVID-19
针对 COVID-19 中异常的肺泡免疫激活和失败的上皮修复
  • 批准号:
    10391970
  • 财政年份:
    2022
  • 资助金额:
    $ 192.72万
  • 项目类别:
Project 3: Targeting linear ubiquitination to attenuate inflammation and promote repair after viral pneumonia
项目3:靶向线性泛素化以减轻病毒性肺炎后的炎症并促进修复
  • 批准号:
    10696965
  • 财政年份:
    2021
  • 资助金额:
    $ 192.72万
  • 项目类别:
Project 3: Targeting linear ubiquitination to attenuate inflammation and promote repair after viral pneumonia
项目3:靶向线性泛素化以减轻病毒性肺炎后的炎症并促进修复
  • 批准号:
    10269676
  • 财政年份:
    2021
  • 资助金额:
    $ 192.72万
  • 项目类别:
Disordered Proteostasis as a Driver of Disease in the Aging Lung
蛋白质稳态紊乱是衰老肺疾病的驱动因素
  • 批准号:
    10208506
  • 财政年份:
    2015
  • 资助金额:
    $ 192.72万
  • 项目类别:
Disordered Proteostasis as a Driver of Disease in the Aging Lung
蛋白质稳态紊乱是衰老肺疾病的驱动因素
  • 批准号:
    10197736
  • 财政年份:
    2015
  • 资助金额:
    $ 192.72万
  • 项目类别:
Alveolar Macrophages as Age-Related Drivers of Disordered Tissue Repair
肺泡巨噬细胞作为紊乱组织修复的年龄相关驱动因素
  • 批准号:
    10197742
  • 财政年份:
    2015
  • 资助金额:
    $ 192.72万
  • 项目类别:
Alveolar Macrophages as Age-Related Drivers of Disordered Tissue Repair
肺泡巨噬细胞作为紊乱组织修复的年龄相关驱动因素
  • 批准号:
    10417059
  • 财政年份:
    2015
  • 资助金额:
    $ 192.72万
  • 项目类别:
Disordered Proteostasis as a Driver of Disease in the Aging Lung
蛋白质稳态紊乱是衰老肺疾病的驱动因素
  • 批准号:
    9751135
  • 财政年份:
    2015
  • 资助金额:
    $ 192.72万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 192.72万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 192.72万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 192.72万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 192.72万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 192.72万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 192.72万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 192.72万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 192.72万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 192.72万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 192.72万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了